Sign in Register. You do not currently have access to this article. Abstr 924. Pathogenesis of Pulmonary Tuberculosis. Long-term molecular surveillance of multidrug-resistant tuberculosis in Spain.
Copyright © 2020 Elsevier B.V. or its licensors or contributors. ICAAC; 2015. Biological variability and the emergence of multidrug-resistant tuberculosis. Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations. " The Pathogenesis of Tuberculosis." Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. In this Commission, we examine several aspects of drug-resistant tuberculosis. 2011 update. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. The prospective evaluation of the TB strain typing service in England: a mixed methods study. Probability distribution of drug-resistant mutants in unselected populations of.

In vitro activities of DA-7157 and DA-7218 against. The role of efflux pumps and mutations outside rifampin resistance determining region in multidrug-resistant tuberulosis. Fluoroquinolone use in paediatrics: focus on safety and place in therapy. Pharmacokinetics–pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Multidrug-resistant tuberculosis and culture conversion with bedaquiline. High frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosis. Multidrug-resistant TB: implementing the right to health through the right to enjoy the benefits of scientific progress. Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation. High prevalence of inha promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa. Prevalence of HIV and HIV-related diseases in the adult medical wards of a tertiary hospital in Durban, South Africa. Selected questions and controversies about bedaquiline: a view from the field. 2012. Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase 2 clinical trials. Systematic analysis of hollow fiber model of tuberculosis experiments. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Relevant research priorities are highlighted, including optimal medical Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Institutional tuberculosis transmission: controlled trial of upper room ultraviolet air disinfection—a basis for new dosing guidelines. Special issues published in Tuberculosis. Integration of antiretroviral therapy with tuberculosis treatment. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. Rates and mechanisms of resistance development in. Oxford University Press is a department of the University of Oxford. Discover how our open access options can help you maximize reach and impact, This journal has partnered with Heliyon Clinical Research, a dedicated section of Heliyon, an open access journal from Cell Press that publishes scientifically accurate and valuable research in clinical research. Confinement for extensively drug-resistant tuberculosis: balancing protection of health systems, individual rights and the public's health. Supports open access. About. Does directly observed therapy (DOT) reduce drug resistant tuberculosis?. are threatened by the increasing burden of multidrug-resistant (MDR) and extensively Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Global progress and challenges in implementing new medications for treating multidrug-resistant tuberculosis. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. Areas on which submissions are welcomed include: Clinical TrialsDiagnosticsAntimicrobial resistanceImmunologyLeprosyMicrobiology, including microbial physiologyMolecular epidemiologyNon-tuberculous MycobacteriaPathogenesisPathologyVaccine development. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. Association between regimen composition and treatment response in patients with multidrug-resistant tuberculosis: a prospective cohort study. Tuberculosis in patients with the acquired immunodeficiency syndrome. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents. Advances in imaging of tuberculosis: the role of. Effect of katG mutations on the virulence of, Compensatory ahpC gene expression in isoniazid-resistant. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan. Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. 56. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. Concordance of resistance profiles in households of patients with multidrug-resistant tuberculosis. Putative compensatory mutations in the rpoC gene of rifampin-resistant. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide, This PDF is available to Subscribers Only. MDR-TB in Finland—still rare despite the situation in our neighbouring countries. care aspects, and medicolegal and ethical issues.

Methods for detection of drug resistance. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of.
Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. Effects of introducing Xpert MTB/RIF test on multi-drug resistant tuberculosis diagnosis in KwaZulu-Natal South Africa. compliance and programmatic failure is now being questioned, and several lines of Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Tuberculous chemotherapy for recalcitrant outpatients administered directly twice weekly. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. 2015 report on tuberculosis research funding trends, 2005–2014: a decade of data. Figure 2.3 . Present aspects of bacterial resistance in tuberculosis. Hinduja National Hospital & Medical Research Centre, Mumbai, India, Faculty of Infectious and Tropical Diseases and Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK, Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan, Center for Clinical Global Health Education (CCGHE), Johns Hopkins University, Baltimore, MD, USA, Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, Tuberculosis and Chest Service, Centre for Health Protection, Department of Health, Hong Kong SAR, China, Division of Clinical Infectious Diseases, German Center for Infection Research, Research Center Borstel, Borstel, Schleswig-Holstein, Germany, Division of Pulmonary and Critical Care, San Francisco General Hospital, University of California, San Francisco, CA, USA, Pulmonary Department, Hinduja Hospital & Research Center, Mumbai, India, Schools of Public Health Medicine, Boston University, Boston, MA, USA, Aurum Institute, Johannesburg, South Africa, Montreal Chest Institute, McGill University, Montreal, QC, Canada, Pulmonary Clinical Medicine Section, Division of Intramural Research, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA, MSF South Africa, Cape Town, South Africa, World Health Organization, Geneva, Switzerland, Treatment Action Campaign, Johannesburg, South Africa, Centre for the AIDS Programme of Research in South Africa (CAPRISA), MRC HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.

A four-year nationwide molecular epidemiological study in Estonia: risk factors for tuberculosis transmission. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. increase in antimicrobial resistance and the emergence of other MDR pathogens, such Seattle, WA, USA; March 5–8, 2012. Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. The hollow fiber system model in the nonclinical evaluation of antituberculosis drug regimens. Overview and epidemiologic assessment of the current global tuberculosis situation with an emphasis on control in developing countries. Directly observed therapy for treating tuberculosis. Synergy between meropenem and amoxicillin/clavulanate.

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. effectiveness. Psychological and educational intervention to improve tuberculosis treatment adherence in ethiopia based on health belief model: a cluster randomized control trial.